- Home
- SIGA vs ATXS Comparison
SIGA vs ATXS Comparison
Compare SIGA & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- ATXS
- Stock Information
- Founded
- SIGA 1995
- ATXS 2008
- Country
- SIGA United States
- ATXS United States
- Employees
- SIGA N/A
- ATXS N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- SIGA Health Care
- ATXS Health Care
- Exchange
- SIGA Nasdaq
- ATXS Nasdaq
- Market Cap
- SIGA 551.0M
- ATXS 584.1M
- IPO Year
- SIGA 1997
- ATXS 2015
- Fundamental
- Price
- SIGA $5.94
- ATXS $9.56
- Analyst Decision
- SIGA
- ATXS Strong Buy
- Analyst Count
- SIGA 0
- ATXS 5
- Target Price
- SIGA N/A
- ATXS $28.00
- AVG Volume (30 Days)
- SIGA 567.4K
- ATXS 380.9K
- Earning Date
- SIGA 11-07-2024
- ATXS 11-13-2024
- Dividend Yield
- SIGA 10.15%
- ATXS N/A
- EPS Growth
- SIGA N/A
- ATXS N/A
- EPS
- SIGA 1.20
- ATXS N/A
- Revenue
- SIGA $173,731,386.00
- ATXS N/A
- Revenue This Year
- SIGA $16.79
- ATXS N/A
- Revenue Next Year
- SIGA $15.08
- ATXS N/A
- P/E Ratio
- SIGA $4.94
- ATXS N/A
- Revenue Growth
- SIGA 399.31
- ATXS N/A
- 52 Week Low
- SIGA $4.26
- ATXS $6.20
- 52 Week High
- SIGA $12.83
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- SIGA 38.74
- ATXS 42.48
- Support Level
- SIGA $5.62
- ATXS $9.17
- Resistance Level
- SIGA $6.23
- ATXS $9.99
- Average True Range (ATR)
- SIGA 0.43
- ATXS 0.60
- MACD
- SIGA -0.07
- ATXS -0.02
- Stochastic Oscillator
- SIGA 19.02
- ATXS 21.20
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.